These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Predictive value of fragmented QRS in primary prevention implantable cardioverter defibrillator recipients with left ventricular dysfunction. Forleo GB; Della Rocca DG; Papavasileiou LP; Panattoni G; Sergi D; Duro L; Mahfouz K; Magliano G; Santini L; Romeo F J Cardiovasc Med (Hagerstown); 2011 Nov; 12(11):779-84. PubMed ID: 21941203 [TBL] [Abstract][Full Text] [Related]
5. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation. Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627 [TBL] [Abstract][Full Text] [Related]
6. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis. Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110 [TBL] [Abstract][Full Text] [Related]
7. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease. Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978 [TBL] [Abstract][Full Text] [Related]
9. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter defibrillators. Goldenberg I; Moss AJ; McNitt S; Zareba W; Daubert JP; Hall WJ; Andrews ML; J Cardiovasc Electrophysiol; 2006 Sep; 17(9):931-6. PubMed ID: 16759297 [TBL] [Abstract][Full Text] [Related]
10. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability. Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517 [TBL] [Abstract][Full Text] [Related]
11. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy. Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population. Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231 [TBL] [Abstract][Full Text] [Related]
13. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy. Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288 [TBL] [Abstract][Full Text] [Related]
14. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077 [TBL] [Abstract][Full Text] [Related]
15. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death. Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108 [TBL] [Abstract][Full Text] [Related]
16. Smoking accelerates implantable cardioverter-defibrillator shocks: encouraging patients to quit a bad habit. Tada H Heart Rhythm; 2006 Apr; 3(4):450-1. PubMed ID: 16567293 [No Abstract] [Full Text] [Related]
17. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit. Parkash R; Sapp JL; Basta M; Doucette S; Thompson K; Gardner M; Gray C; Brownell B; Kidwai H; Cox J Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):706-13. PubMed ID: 22685111 [TBL] [Abstract][Full Text] [Related]
18. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register. Weeke P; Johansen JB; Jørgensen OD; Nielsen JC; Møller M; Videbæk R; Højgaard MV; Riahi S; Jacobsen PK Europace; 2013 Aug; 15(8):1150-7. PubMed ID: 23407630 [TBL] [Abstract][Full Text] [Related]